HitGen(SH:688222)2024-05-16 10:31Financial Performance - In 2023, the company achieved revenue of CNY 371 million, a year-on-year increase of 12.64% [15] - The net profit attributable to shareholders was CNY 40.72 million, up 61.16% year-on-year [15] - The overall gross profit margin for core business was 49.28%, an increase of 1.61 percentage points year-on-year [15] - Operating cash flow net amount reached CNY 125 million, a year-on-year growth of 137.42% [15] Revenue Breakdown by Platform - DEL platform revenue was CNY 183.58 million, a year-on-year increase of 25.45% [15] - FBDD/SBDD platform revenue was CNY 91.78 million, a decrease of 11.13% year-on-year [15] - STO platform revenue was CNY 34.38 million, a decrease of 10.62% year-on-year, but service revenue grew by 60.16% [16] - TPD platform revenue was CNY 18.52 million, an increase of 111.85% year-on-year [16] Research and Development Focus - The company has been actively integrating AI in drug discovery, particularly through the DEL+AI platform [9][14] - The DEL technology has been developed and applied for over 10 years, making the company a leader in the field [6] - The average success rate for screening projects in the past three years is nearly 80%, higher than the industry average for HTS [7][12] Strategic Initiatives - The company is focusing on expanding its DEL technology applications to meet specific client needs, such as DEL For Protein Degradation and DEL For GPCRs [8] - The integration of high-throughput synthesis and compound testing platforms aims to accelerate the drug discovery process [9][14] - The company is enhancing collaboration between its UK subsidiary and domestic teams to improve project success rates and efficiency [10][11] Market Position and Competitiveness - Chengdu XianDao is recognized as one of the leading companies in DEL technology, with numerous collaborations with major pharmaceutical companies [6][7] - The company has published over 30 original scientific papers in the DEL field, contributing to technological innovation [6] - The company has accumulated experience in screening hundreds of targets across more than 53 target types [12][13]